

Martyn Bullock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4186672/publications.pdf>

Version: 2024-02-01

21
papers

1,126
citations

759233

12
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

2183
citing authors

#	ARTICLE	IF	CITATIONS
1	Translational Utility of Liquid Biopsies in Thyroid Cancer Management. <i>Cancers</i> , 2021, 13, 3443.	3.7	12
2	Key MicroRNA™s and Their Targetome in Adrenocortical Cancer. <i>Cancers</i> , 2020, 12, 2198.	3.7	15
3	Congenital Hypoparathyroidism Associated With Elevated Circulating Nonfunctional Parathyroid Hormone Due to Novel PTH Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2408-2412.	3.6	7
4	The Histamine 3 Receptor Is Expressed in the Heart and Its Activation Opposes Adverse Cardiac Remodeling in the Angiotensin II Mouse Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9757.	4.1	6
5	ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer. <i>Thyroid</i> , 2019, 29, 1623-1633.	4.5	33
6	Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-specific Immunohistochemistry in Detection of Sporadic Disease. <i>World Journal of Surgery</i> , 2018, 42, 1432-1439.	1.6	9
7	Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma. <i>Pathology</i> , 2018, 50, 342-344.	0.6	6
8	An InDel in Phospholipase-C-B-1 Is Linked with Euthyroid Multinodular Goiter. <i>Thyroid</i> , 2018, 28, 891-901.	4.5	7
9	NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2. <i>American Journal of Surgical Pathology</i> , 2017, 41, 75-81.	3.7	31
10	DNA Methylation Analysis: Choosing the Right Method. <i>Biology</i> , 2016, 5, 3.	2.8	480
11	Destabilizing RET in targeted treatment of thyroid cancers. <i>Endocrine Connections</i> , 2016, 5, 10-19.	1.9	6
12	<i>TERT</i> promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. <i>Clinical Endocrinology</i> , 2016, 85, 283-290.	2.4	58
13	FOXO factors and breast cancer: outfoxing endocrine resistance. <i>Endocrine-Related Cancer</i> , 2016, 23, R113-R130.	3.1	39
14	Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT. <i>Oncotarget</i> , 2016, 7, 85948-85962.	1.8	15
15	Somatic Mutations of FOXE1 in Papillary Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 904-910.	4.5	12
16	Association of FOXE1 Polyalanine Repeat Region with Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1814-E1819.	3.6	52
17	Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2012, 19, 779-784.	3.1	65
18	Multikinase inhibitors: a new option for the treatment of thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2011, 7, 617-624.	9.6	130

#	ARTICLE	IF	CITATIONS
19	Contribution of a Common Variant in the Promoter of the 1- α -Hydroxylase Gene (CYP27B1) to Fracture Risk in the Elderly. <i>Calcified Tissue International</i> , 2011, 88, 109-116.	3.1	20
20	BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. <i>Surgery</i> , 2010, 148, 1139-1146.	1.9	84
21	Altered Tear Composition in Smokers and Patients With Graves Ophthalmopathy. <i>JAMA Ophthalmology</i> , 2006, 124, 1451.	2.4	39